We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+1.04%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.2B
AUM Growth
-$33.6M
(-2.7%)
Cap. Flow
+$15.8M
Cap. Flow
% of AUM
1.32%
Top 10 Holdings %
Top 10 Hldgs %
22.6%
Holding
147
New
20
Increased
35
Reduced
44
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
|
+$37.2M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$24.3M |
| 3 |
Health Catalyst
HCAT
|
+$24.1M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$22.2M |
| 5 |
CELL
PhenomeX Inc. Common Stock
CELL
|
+$16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teleflex
TFX
|
+$21.8M |
| 2 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$21.4M |
| 3 |
Repligen
RGEN
|
+$20M |
| 4 |
OSH
Oak Street Health, Inc.
OSH
|
+$18.8M |
| 5 |
NEUE
NeueHealth
NEUE
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.67% |
| 2 | Industrials | 4.36% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
PTC Therapeutics
PTCT
$5.68B
| $9.39M | 0.78% |
252,291
-80,000
| -24% | -$3.29M |
|
52
Olema Pharmaceuticals
OLMA
$1B
| $9.33M | 0.78% |
338,381
-151,639
| -31% | -$4.09M |
|
53
Rallybio
RLYB
$84.5M
| $9.27M | 0.77% |
+65,892
| New | +$7.73M |
|
|
TPTX
54
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $9.08M | 0.76% |
136,650
-75,000
| -35% | -$5.34M |
|
55
DexCom
DXCM
$31.5B
| $8.99M | 0.75% |
65,752
-39,400
| -37% | -$4.97M |
|
|
ACCD
56
DELISTED
Accolade Inc
ACCD
| $8.86M | 0.74% |
210,000
-20,000
| -9% | -$940K |
|
57
Abbott
ABT
$183B
| $8.79M | 0.73% |
74,448
-19,500
| -21% | -$2.4M |
|
|
58
Teleflex
TFX
$6.05B
| $8.76M | 0.73% |
23,261
-56,107
| -71% | -$21.8M |
|
59
Bio-Techne
TECH
$11.2B
| $8.53M | 0.71% |
+70,400
| New | +$8.57M |
|
60
Intellia Therapeutics
NTLA
$1.49B
| $8.44M | 0.7% |
+62,900
| New | +$9.52M |
|
61
Molina Healthcare
MOH
$10.2B
| $8.33M | 0.69% |
30,697
| – | – |
|
|
CELL
62
DELISTED
PhenomeX Inc. Common Stock
CELL
| $8.24M | 0.69% |
+421,535
| New | +$16M |
|
63
BioMarin Pharmaceuticals
BMRN
$11.6B
| $8.2M | 0.68% |
106,112
+33,390
| +46% | +$2.63M |
|
64
Guardant Health
GH
$21.7B
| $8.17M | 0.68% |
65,386
-6,800
| -9% | -$808K |
|
65
Exelixis
EXEL
$13.3B
| $8.1M | 0.67% |
383,370
-35,000
| -8% | -$650K |
|
|
66
Repligen
RGEN
$7.96B
| $7.8M | 0.65% |
27,000
-77,793
| -74% | -$20M |
|
|
ITOS
67
DELISTED
iTeos Therapeutics
ITOS
| $7.39M | 0.61% |
273,700
+266,000
| +3,455% | +$6.95M |
|
|
JBIO
68
Jade Biosciences
JBIO
$1.2B
| $7.16M | 0.6% |
9,753
-4,533
| -32% | -$2.54M |
|
|
HOLX
69
DELISTED
Hologic
HOLX
| $7.07M | 0.59% |
95,800
-500
| -0.5% | -$37.5K |
|
70
Centene
CNC
$30.7B
| $7.05M | 0.59% |
113,075
-40,900
| -27% | -$2.73M |
|
71
Neuropace
NPCE
$439M
| $7.05M | 0.59% |
444,572
-27,394
| -6% | -$575K |
|
72
Cytek Biosciences
CTKB
$545M
| $7.02M | 0.58% |
+328,080
| New | +$7.72M |
|
73
Teladoc Health
TDOC
$1.22B
| $6.74M | 0.56% |
53,138
+2,500
| +5% | +$364K |
|
|
KLRS
74
Kalaris Therapeutics
KLRS
$83.5M
| $6.6M | 0.55% |
11,451
+9,931
| +653% | +$4.6M |
|
75
Dentsply Sirona
XRAY
$2.68B
| $6.56M | 0.55% |
113,000
+5,000
| +5% | +$308K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Sectoral Asset Management held 147 positions worth $1.2B, down 2.7% from $1.24B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Sectoral Asset Management's Q3 2021 filing shows 20 new, 35 increased, 44 reduced and 20 closed positions. Its largest new stake was eFFECTOR Therapeutics, Inc. Common Stock: 115,310 shares worth $40.5M. The largest sale was Teleflex, an estimated $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Industrials and Financials.
- Sectoral Asset Management's largest Q3 2021 buy was eFFECTOR Therapeutics, Inc. Common Stock: 115,310 shares worth $40.5M.
- Sectoral Asset Management added most to Treace Medical Concepts in Q3 2021, an estimated $8.26M increase.
- Sectoral Asset Management's biggest Q3 2021 reduction was Teleflex, cutting an estimated $21.8M.
- Sectoral Asset Management fully exited Oak Street Health, Inc. in Q3 2021, selling an estimated $18.8M.
- Sectoral Asset Management's ten largest holdings make up 23% of its $1.2B portfolio in Q3 2021.
- Sectoral Asset Management opened 20 new positions and closed 20 in Q3 2021.
- Sectoral Asset Management's portfolio value fell 2.7% quarter-over-quarter to $1.2B.
Based on Sectoral Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.